Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Department of Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Surg Oncol Clin N Am. 2024 Jan;33(1):87-97. doi: 10.1016/j.soc.2023.07.003. Epub 2023 Aug 31.
Immunotherapy has revolutionized the standard of care in multiple aspects of oncology. Given successes in the setting of unresectable hepatocellular carcinoma (HCC) and the advantages of neoadjuvant therapy, many trials are demonstrating the safety and feasibility of combination of immune checkpoint inhibitors (ICIs)/tyrosine kinases in patients with resectable HCC. Numerous clinical trials are currently investigating the role of different immune modulators either as monotherapy or as combination therapy in the neoadjuvant setting. Key questions that remain to be addressed include efficacy, safety, predictive biomarkers, and length of treatment.
免疫疗法在肿瘤学的多个方面改变了治疗标准。鉴于不可切除肝细胞癌（HCC）治疗方面的成功以及新辅助治疗的优势，许多试验正在证明免疫检查点抑制剂（ICI）/酪氨酸激酶联合治疗可切除 HCC 患者的安全性和可行性。目前，许多临床试验正在研究不同免疫调节剂作为单一疗法或联合疗法在新辅助治疗中的作用。仍有待解决的关键问题包括疗效、安全性、预测生物标志物和治疗时间。
